FDA push­es eczema de­ci­sion for Eli Lil­ly's Olu­mi­ant, Pfiz­er's abroc­i­tinib back 3 months — rais­ing more ques­tions for the JAK class

The FDA re­view ex­ten­sions for JAK in­hibitors are stack­ing up.

Af­ter Eli Lil­ly and In­cyte dis­closed late Tues­day that their sup­ple­men­tal NDA for Olu­mi­ant in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER